LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Home・Elenco Azioni・Merck & Co Inc.

Merck & Co Inc.

Chiusa

SettoreSettore sanitario

122.49 5.78

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

115.86

Massimo

122.64

Metriche Chiave
By Trading Economics
Entrata	-7.2B -4.2B
Vendite	-114M 16B
P/E Media del settore	31.707 49.701
EPS	-1.28
Rendimento da dividendi	2.94
Margine di Profitto	-26.053
Dipendenti	73,000
EBITDA	-6.2B -1.9B

Raccomandazioni
By TipRanks
Raccomandazioni	Acquista
Previsioni per 12 mesi	+19.68% upside

Dividendi
By Dow Jones
Rendimento da dividendi Media del settore	2.94% 2.39%
Utili prossimi	4 ago 2026
Prossima data del Dividendo	7 lug 2026
Prossima data del' Ex Dividendo	15 giu 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	5.7B 278B
Apertura precedente	116.71
Chiusura precedente	122.49

Punteggio Tecnico

By Trading Central

Fiducia

Bearish Evidence

76.03 / 83.28 Supporto e resistenza

Merck & Co Inc. Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

30 apr 2026, 14:20 UTC

Utili

Merck 1Q Sales Rise on Continued Keytruda Growth -- Update

30 apr 2026, 10:45 UTC

Utili

Merck 1Q Sales Rise on Continued Keytruda Growth

5 mag 2026, 18:12 UTC

Utili

BioNTech to Slash 22% of Workforce as Losses Widen. The Stock Falls. -- Barrons.com

5 mag 2026, 13:54 UTC

Utili

BioNTech to Slash 25% of Workforce as Losses Widen. The Stock Falls. -- Barrons.com

5 mag 2026, 12:48 UTC

Acquisizioni, Fusioni, Takeovers

Merck Cites Costs Associated With Advancing TERN-701 and Financing >MRK

5 mag 2026, 12:48 UTC

Acquisizioni, Fusioni, Takeovers

Merck: GAAP and Adj EPS Expected to Be Negatively Impacted by About 12c/Shr in 2026 >MRK

5 mag 2026, 12:47 UTC

Acquisizioni, Fusioni, Takeovers

Merck: Transaction Expected to Be Accounted for as Asset Acquisition, Resulting in Chg of About $5.8 B, or $2.35/Shr, Included in 2Q and FY26 Results >MRK

5 mag 2026, 12:45 UTC

Acquisizioni, Fusioni, Takeovers

Merck Completes Acquisition Of Terns Pharmaceuticals, Inc. >MRK TERN

1 mag 2026, 18:35 UTC

Utili

Moderna's Covid Vaccine Is Driving Growth Again. The Stock Is Down Anyway. -- Barrons.com

1 mag 2026, 14:53 UTC

Utili

Moderna's Covid Vaccine Is Driving Growth Again. The Stock Is Down Anyway. -- Barrons.com

30 apr 2026, 13:27 UTC

Utili

Merck Stock Falls After Earnings. It's Working on Ways to Blunt Future Lost Keytruda Sales. -- Barrons.com

30 apr 2026, 10:47 UTC

Utili

Update: Merck Stock Rises on Earnings. These Problems Loom Larger Than Keytruda Patent Cliff. -- Barrons.com

30 apr 2026, 10:30 UTC

Utili

Merck: Also Anticipate EPS Will Be Negatively Affected by About 12c Over Remainder of 2026 Following Close of Terns Deal >MRK

30 apr 2026, 10:30 UTC

Utili

Merck Raises 2026 View To Adj EPS $5.04-Adj EPS $5.16 Vs Prior View $5-$5.15 >MRK

30 apr 2026, 10:30 UTC

Utili

Merck: 2026 Outlook Doesn't Reflect Any Impact From Proposed Acquisition of Terns Pharmaceuticals, Which Is Expected to Close in May and Result in One-Time Charge of About $2.35/Shr >MRK

30 apr 2026, 10:30 UTC

Utili

Merck: Sales Outlook Includes Positive Impact From Forex of About 1% at Mid-April 2026 Exchange Rates >MRK

30 apr 2026, 10:30 UTC

Utili

Merck: Adj EPS Outlook Also Reflects One-Time Charge of $3.62/Shr for Acquisition of Cidara >MRK

30 apr 2026, 10:30 UTC

Utili

Merck: Adj EPS Outlook Includes Positive Impact From Forex of About 10c/Shr at Mid-April 2026 Exchange Rates >MRK

30 apr 2026, 10:30 UTC

Utili

Merck Narrows 2026 View To Sales $65.8B-$67B Vs Prior View $65.5B-$67B >MRK

30 apr 2026, 10:30 UTC

Utili

Merck: Latest 1Q Includes Charge of $3.62/Share for the Acquisition of Cidara >MRK

30 apr 2026, 10:30 UTC

Utili

Merck: 1Q Gardasil/Gardasil 9 Sales Also Reflect Lower Sales in U.S. Primarily Due to Unfavorable Public-Sector Purchasing Patterns, Partially Offset by Higher Net Pricing >MRK

30 apr 2026, 10:30 UTC

Utili

Merck 1Q Gardasil/Gardasil 9 Sales Down 19% >MRK

30 apr 2026, 10:30 UTC

Utili

Merck: Lower 1Q Januvia/Janumet Sales Due to Lower Demand and Net Pricing in U.S., Lower Demand in China and Most Other International Markets Due to Generic Competition >MRK

30 apr 2026, 10:30 UTC

Utili

Merck: Pleased With Progress and Excited for What's Ahead, as We Enter Particularly Robust Period of Phase 3 Data Readouts and Deliver on Promise of Our Pipeline for Patients >MRK

30 apr 2026, 10:30 UTC

Utili

Merck 1Q Winrevair Sales $525M, Up 88%, Reflecting Continued Uptake in U.S. and Early Launch Uptake in Certain Intl Mkts, Especially Japan and Europe >MRK

30 apr 2026, 10:30 UTC

Utili

Merck: 1Q Animal Health Sales Growth Attributable to Performance in Both Livestock and Companion Animal Product Portfolios >MRK

30 apr 2026, 10:30 UTC

Utili

Merck: Lower 1Q Gardasil/Gardasil 9 Sales Primarily Due to Lower Demand in China as Well as Lower Sales in Japan Following National Catch-Up Immunization Program >MRK

30 apr 2026, 10:30 UTC

Utili

Merck 1Q Pharmaceutical Sales Up 5% >MRK

30 apr 2026, 10:30 UTC

Utili

Merck 1Q Animal Health Sales Up 13% >MRK

30 apr 2026, 10:30 UTC

Utili

Merck 1Q Sales $16.29B >MRK

Confronto tra pari

Modifica del prezzo

Merck & Co Inc. Previsione

Obiettivo di Prezzo

By TipRanks

19.68% in crescita

Previsioni per 12 mesi

Media 135.24 USD 19.68%

Alto 179 USD

Basso 112 USD

Basato su 20 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Merck & Co Inc. - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

20 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 20 che hanno fornito valutazioni azionarie a Merck & Co Inc. - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

76.03 / 83.28Supporto e resistenza

Recent bearish events outweigh bullish events.

All events are bearish.

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Merck & Co Inc.

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. vIt has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications. It also has licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.